Eswatini和南非的东开普正推出一年两次的艾滋病毒预防注射, Eswatini and South Africa’s Eastern Cape are rolling out a twice-yearly HIV prevention injection to boost adherence and cut new infections.

Eswatini和南非的东开普开始推出长效艾滋病毒接触前预防器Lenacapavir(PrePEP), Eswatini and South Africa’s Eastern Cape have begun rolling out lenacapavir, a long-acting HIV pre-exposure prophylaxis (PrEP) injected twice yearly, to improve adherence and reduce new infections. 自12月以来,Eswatini已经向大约2,000人服用了这一药物,而东开普的初始阶段覆盖了49个诊所的8,300人,这些诊所由全球基金提供资金。 Eswatini has administered the drug to about 2,000 people since December, while the Eastern Cape’s initial phase covers 8,300 people across 49 clinics, funded by the Global Fund. 由Gilead Science公司开发的可注射药物遵循卫生组织的准则,旨在扩大获得治疗的机会,减少耻辱感,降低艾滋病毒的传播,特别是在青年中。 The injectable, developed by Gilead Sciences, follows WHO guidelines and aims to expand access, reduce stigma, and lower HIV transmission, particularly among youth. 两个地区都计划在全国范围内扩展,通过定价和可能的非专利生产来解决长期可持续性问题。 Both regions plan nationwide expansions, with long-term sustainability to be addressed through pricing and potential generic production.